Global Drug Development Pipeline Falls for First Time in Three Decades

Global Drug Development Pipeline Falls for First Time in Three Decades
—————————————
The number of drugs in active research and development worldwide has declined for the first time since the mid-1990s, according to Citeline’s Pharma R&D Annual Review 2026.

Citeline reported that 22,940 drugs were in active global R&D at the start of 2026, marking a modest year-on-year decline. Industry reports based on the same data said the figure was down 3.9 percent from 23,875 drugs in 2025.

The decline ends nearly three decades of continuous growth in the global pharmaceutical pipeline. However, Citeline cautioned that the drop should not be read simply as a collapse in innovation, saying it partly reflects data normalization after changes in how projects were tracked.

BioSpace also reported that the figures may point more to a plateau in global drug development than a sharp downturn, noting Citeline’s warning that internal reporting changes may have affected the comparison with 2025.

Analysts said the development reflects a pharmaceutical sector in transition, with companies reassessing early-stage programs, focusing resources more selectively, and placing greater emphasis on projects with stronger chances of reaching approval.

The report suggests that while the overall number of drugs under development has fallen, the industry remains active, with innovation continuing across major therapeutic areas and late-stage pipelines.